John E. Hamer

Managing Director

John E. Hamer joined Burrill & Company in November 2003 as Entrepreneur-In-Residence and co-founded Arête Therapeutics, a cardiovascular therapeutics company developing a first-in-class anti-hypertensive. He served as President and CEO until 2006 securing $16 million in a Series A financing and building the development team. Dr. Hamer stays engaged with Arête Therapeutics and moved to Burrill as Managing Director in 2006.

Prior to joining Burrill & Company Dr. Hamer helped to build Paradigm Genetics/Icoria (acquired by Clinical Data, CLDA: NASDAQ) from its beginning in 1998, serving in various capacities as Director of Microbial Research, Vice President of Research, Chief Scientific Officer, Vice President for Business Development, and Interim President and CEO. He received his Ph.D. in Microbiology from the University of California, Davis in 1987 and was a visiting scientist at Dupont’s Central Research and Development from 1987 to 1989. He served on the faculty of Purdue University where he held the positions of Assistant Professor (‘89-’90), Associate Professor (‘92-’98), Professor (‘98-’00), and Adjunct Professor of Microbiology and Immunology at Indiana University/Purdue University Medical School.

He currently holds an honorary position as Adjunct Professor of Biological Sciences. Dr. Hamer has published over 70 research articles and has received numerous awards of distinction throughout his career, including a David and Lucille Packard Fellowship (1990-1995) and the National Science Foundation Presidential Faculty Fellowship (1993-1998). He has served on numerous scientific review and biotechnology advisory boards including those at the National Institutes of Health, the National Science Foundation, Purdue Alumni Science Advisory Board, and North Carolina Genomic and Bioinformatics Consortium. Dr. Hamer serves on the Boards of Directors of the Malaysian Life Sciences Capital Fund, Chromatin, Cobalt Technologies, Arête Therapeutics (Founder and CEO), and Diadexus (Observer).